Displaying drugs 151 - 175 of 4961 in total
Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 4 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). It is...
Approved
Investigational
Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 1 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). The saccharides...
Approved
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 5 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). The saccharides...
Approved
Etonogestrel
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Approved
Investigational
Matched Description: … Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically …
Cyclizine
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Approved
Matched Salts cas: … 5897-19-8 …
Matched Mixtures name: … Echnatol B 6 - Dragees …
Matched Mixtures name: … Echnatol B 6 - Dragees …
Methylphenidate
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally...
Approved
Investigational
Matched Description: … excipients expand, allowing methylphenidate to release slowly through the orifice over a period of 6- …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Iupac: … (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo …
Matched Mixtures name: … BUDEK PLUS® 200/6 MCG ... BUDEK PLUS® 200/6 MCG ... BUDEMAR DUO® FORMOTEROL FUMARATO 6 MCG + BUDESONIDA 200 MCG. …
Matched Mixtures name: … BUDEK PLUS® 200/6 MCG ... BUDEK PLUS® 200/6 MCG ... BUDEMAR DUO® FORMOTEROL FUMARATO 6 MCG + BUDESONIDA 200 MCG. …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Norgestimate
Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with ethinylestradiol as a combined oral contraceptive that can also be used to treat moderate acne...
Approved
Investigational
Viloxazine
Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Elranatamab
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Naldemedine
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of DB00704 to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and...
Approved
Investigational
Bevacizumab
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Description: … Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may ... is being investigated for the treatment of lung complications associated with severe cases of COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Piperaquine
Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative DB11638 as part of...
Approved
Experimental
Investigational
Benzyl alcohol
Approved
Poliovirus type 1 antigen (formaldehyde inactivated)
Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were...
Approved
Investigational
Matched Description: … a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 …
Poliovirus type 3 antigen (formaldehyde inactivated)
Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 3. The vaccine contains purified and inactivated poliovirus type 3 that were...
Approved
Investigational
Matched Description: … a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 …
Ethambutol
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … [A229048]
Ethambutol was granted FDA approval on 6 November 1967.[L31663] …
Morphine
Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength...
Approved
Investigational
Matched Salts cas: … 52-26-6 ... 596-15-6 …
Manidipine
Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Approved
Investigational
Agalsidase beta
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Agalsidase alfa
Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Poliovirus type 2 antigen (formaldehyde inactivated)
Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were...
Approved
Investigational
Matched Description: … is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Iupac: … 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid …
Displaying drugs 151 - 175 of 4961 in total